...to the product in Japan, South Korea and Singapore to Eisai and in Taiwan to InnoPharmax...
...cell NHL. Mundipharma markets it as Ribomustin in Germany to treat CLL, NHL and MM. InnoPharmax Inc....

...to the product in Japan, South Korea and Singapore to Eisai and in Taiwan to InnoPharmax...
...Switzerland), co-market rituximab as Rituxan in the U.S., while Roche markets it as MabThera elsewhere. InnoPharmax Inc....

...to the product in Japan, South Korea and Singapore to Eisai and in Taiwan to InnoPharmax...
...cell NHL. Mundipharma markets it as Ribomustin in Germany to treat CLL, NHL and MM. InnoPharmax Inc....

...to the product in Japan, South Korea and Singapore to Eisai and in Taiwan to InnoPharmax...
...Mundipharma markets it as Ribomustin in Germany to treat CLL, NHL and multiple myeloma (MM). InnoPharmax Inc....

...to the product in Japan, South Korea and Singapore to Eisai and in Taiwan to InnoPharmax...
...Mundipharma markets it as Ribomustin in Germany to treat CLL, NHL and multiple myeloma (MM). InnoPharmax Inc....

...to the product in Japan, South Korea and Singapore to Eisai and in Taiwan to InnoPharmax...
...Switzerland), co-market rituximab as Rituxan in the U.S., while Roche markets it as MabThera elsewhere. InnoPharmax Inc....

...to the product in Japan, South Korea and Singapore to Eisai and in Taiwan to InnoPharmax...
...Switzerland), co-market rituximab as Rituxan in the U.S., while Roche markets it as MabThera elsewhere. InnoPharmax Inc....

...to the product in Japan, South Korea and Singapore to Eisai and in Taiwan to InnoPharmax...
...Switzerland), co-market rituximab as Rituxan in the U.S., while Roche markets it as MabThera elsewhere. InnoPharmax Inc....

...to the product in Japan, South Korea and Singapore to Eisai and in Taiwan to InnoPharmax...
...Mundipharma markets it as Ribomustin in Germany to treat CLL, NHL and multiple myeloma (MM). InnoPharmax Inc....

...market the product in Japan, South Korea and Singapore to Eisai and in Taiwan to InnoPharmax...
...Switzerland), co-market rituximab as Rituxan in the U.S., while Roche markets it as MabThera elsewhere. InnoPharmax Inc....